Samarium-153Sm-EDTMP as an equivalent variant to pharmaceutical analgesic treatment
AuthorTsoucalas, G.; Sarafianou, E.; Galanos, A.; Parpa, E.; Baziotis, N.; Sgantzos, M.; Gennimata, V.; Lymperi, M.; Patiraki, E.; Kouloulias, V.; Mystakidou, K.
Purpose: Cancer pain is the most serious symptom for patients, especially during their terminal phase, when palliative medicine is needed. Our study tried to verify the usefulness of single-shot intravenous administration of Samarium (Sm)-153EDTMP in patients with bone metastases (group-A, N=53, males=25, females=28, age range: 30-69 years), as well as to compare a series of variables, using as a control group (group-B, N=37, males=17,females=20, age range: 30-69 years) with patients who were under drug treatment given from a physician specialized in palliative medicine. Methods: Both groups answered the following questionnaires: Greek Brief Pain Inventory (GBPI), Brief Multidimensional Life Satisfaction Scale (BMLSS), Hospital Anxiety Depression Scale (HADS) and ECOG performance status. Results: Pain severity and pain interference improvement p=0.0005 for both groups. HADS-anxiety: Samarium group, p= 0.397, drugs group p= 0.031. HADS-depression improvement for both groups p=0.031 and p=0.003, respectively. BMLSS improvement p=0.029 and p=0.265, while EGOG PS improvement was p=0.005 and p=0.014, respectively (numeric values). Conclusion: Intravenous administration of Sm-153EDT-MP was equivalent to drug treatment against cancer pain for patients with multiple bone metastasis, an option for those patients who are intolerant or resistant to drug treatment. Samarium-treated patients needed less or not at all pain killers, having a better cost-effective result.